pioglitazone has been researched along with Fibrosis in 64 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to explore the role of pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, in cardiac fibrosis of diabetic mice." | 8.02 | Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway. ( Guo, JJ; Hu, CC; Sun, GX; Sun, RC; Yu, HC; Zhang, XD, 2021) |
| " Further application of PPAR-γ agonist (pioglitazone) and antagonist (GW9662) in H9C2 cells revealed that the up-regulation of PPAR-γ expression induced by T-2 toxin is a self-preservation phenomenon, and increasing exogenous PPAR-γ can alleviate the increase in TGF-β1 caused by T-2 toxin, thereby playing a role in relieving cardiac fibrosis." | 8.02 | PPAR-γ with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats. ( Guo, P; Hu, S; Lu, Q; Ren, Z; Wang, X; Wu, Q; Zhu, X, 2021) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 7.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 7.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 7.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "Pioglitazone and candesartan have additive protective effects on renal fibrosis due to UUO in mice, suggesting that their use in combination would be an effective treatment for chronic kidney disease." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "To investigate whether the PPARgamma ligand pioglitazone (PGZ) inhibited bleomycin (BLM)-induced acute lung injury and subsequent fibrosis." | 7.75 | Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. ( Aoki, F; Aoki, N; Aoki, Y; Aoyagi, K; Arai, M; Kurabayashi, M; Maeno, T; Nakagawa, J; Sando, Y; Shimizu, Y; Suga, T; Ueno, M, 2009) |
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 7.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters." | 5.91 | A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023) |
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 5.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 5.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 5.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Myocardial fibrosis is the major factor that regulates left ventricular (LV) diastolic function." | 5.35 | Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. ( Aoki, I; Goto, T; Ito, H; Katsuta, M; Terui, G, 2009) |
| "Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma." | 5.32 | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "The aim of this study was to explore the role of pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, in cardiac fibrosis of diabetic mice." | 4.02 | Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway. ( Guo, JJ; Hu, CC; Sun, GX; Sun, RC; Yu, HC; Zhang, XD, 2021) |
| " Further application of PPAR-γ agonist (pioglitazone) and antagonist (GW9662) in H9C2 cells revealed that the up-regulation of PPAR-γ expression induced by T-2 toxin is a self-preservation phenomenon, and increasing exogenous PPAR-γ can alleviate the increase in TGF-β1 caused by T-2 toxin, thereby playing a role in relieving cardiac fibrosis." | 4.02 | PPAR-γ with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats. ( Guo, P; Hu, S; Lu, Q; Ren, Z; Wang, X; Wu, Q; Zhu, X, 2021) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 3.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 3.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| " The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis." | 3.83 | TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. ( Du, J; Kong, L; Nan, Y; Niu, X; Wang, R; Zhang, Y; Zhao, S, 2016) |
| "The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown." | 3.81 | Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway. ( Chen, XQ; Guo, M; Jiang, WF; Liu, F; Liu, X; Wang, QX; Zhang, MJ; Zhou, L, 2015) |
| " Diabetic nephropathic rats were orally given vehicle, pioglitazone, aliskiren, or combined pioglitazone and aliskiren for four weeks to compare their effects on cardiovascular injury, particularly myocardial fibrosis." | 3.78 | Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 3.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| " Here we investigated the effect of pioglitazone on angiotensin II (Ang II)-induced cardiac hypertrophy and assessed the potential contribution of adiponectin to the action of pioglitazone on the heart." | 3.76 | Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. ( Cheng, X; Furukawa, M; Li, P; Murohara, T; Nagata, K; Ohashi, T; Ouchi, N; Shibata, R; Shimano, M; Unno, K, 2010) |
| "Pioglitazone and candesartan have additive protective effects on renal fibrosis due to UUO in mice, suggesting that their use in combination would be an effective treatment for chronic kidney disease." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "To investigate whether the PPARgamma ligand pioglitazone (PGZ) inhibited bleomycin (BLM)-induced acute lung injury and subsequent fibrosis." | 3.75 | Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. ( Aoki, F; Aoki, N; Aoki, Y; Aoyagi, K; Arai, M; Kurabayashi, M; Maeno, T; Nakagawa, J; Sando, Y; Shimizu, Y; Suga, T; Ueno, M, 2009) |
| " Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPARgamma(-/-) mice but induced hypertrophy in a PPARgamma-dependent manner." | 3.74 | Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. ( Caglayan, E; Collins, AR; Erdmann, E; Hsueh, WA; Liu, J; Lyon, CJ; Peterson, LE; Rosenkranz, S; Ross, RS; Stauber, B; Tangirala, RK; Yin, F, 2008) |
| "Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats." | 3.74 | Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. ( Cheng, XW; Kato, MF; Koike, Y; Miyachi, M; Murate, T; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Obata, K; Shibata, R; Tsuboi, K; Yamada, T; Yazawa, H; Yokota, M, 2008) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| " We evaluated the effect of 24- to 48-h 8 microM l-805645 or 10 microM pioglitazone on 25 mM D-glucose-induced markers of fibrosis in HK-2 cells." | 3.73 | PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. ( Chen, X; Panchapakesan, U; Pollock, CA; Sumual, S, 2005) |
| "Pioglitazone (Pio) is an approved diabetes medicine with proven efficacy in non-alcoholic steatohepatitis (NASH); PXL065 is a novel related oral agent which has been shown to retain Pio's efficacy in preclinical NASH models, with reduced potential for PPARγ-driven side effects." | 3.30 | Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). ( Bedossa, P; Bolze, S; Cusi, K; Dewitt, S; Dubourg, J; Fouqueray, P; Grouin, JM; Hallakou-Bozec, S; Harrison, SA; Moller, DE; Ratziu, V; Thang, C, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing." | 3.01 | Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. ( An, J; Sohn, JH, 2023) |
| "NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma." | 2.55 | Therapies in non-alcoholic steatohepatitis (NASH). ( Oseini, AM; Sanyal, AJ, 2017) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the monogenic disorders and is characterized by bilateral renal cysts; cysts in other organs including liver, pancreas, spleen, testis and ovary; vascular abnormalities including intracranial aneurysms and subarachnoid hemorrhage; and cardiac disorders such as left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation." | 2.48 | PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. ( Nagao, S; Yamaguchi, T, 2012) |
| "Treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, resulted in attenuation of pressure overload-induced LA fibrosis." | 2.48 | Novel strategy to prevent atrial fibrosis and fibrillation. ( Fukunaga, N; Hara, M; Kume, O; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O, 2012) |
| "Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters." | 1.91 | A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023) |
| "Associations between HRQoL and NAFLD disease activity score in the secondary analysis were of similar magnitude." | 1.72 | Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. ( Aveyard, P; Cobbold, JF; Heath, L; Koutoukidis, DA; Tomlinson, JW, 2022) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 1.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 1.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| "Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH)." | 1.46 | Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. ( Bril, F; Cusi, K; Frye, RF; Kalavalapalli, S; Kawaguchi-Suzuki, M, 2017) |
| "Pioglitazone treatment improved survival, reduced PASP, muscularization of small pulmonary arteries, and medial wall thickness." | 1.43 | Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. ( Baldus, S; Behringer, A; Berghausen, EM; Blaschke, F; Caglayan, E; Er, F; Gassanov, N; Kappert, K; Odenthal, M; Rosenkranz, S; Ten Freyhaus, H; Trappiel, M; Wellnhofer, E, 2016) |
| "Treatment with pioglitazone prevented abnormal valve calcification, but did not protect valve function." | 1.42 | Spontaneous Aortic Regurgitation and Valvular Cardiomyopathy in Mice. ( Baumbach, GL; Brooks, RM; Chen, B; Chu, Y; Davis, MK; Doshi, H; El Accaoui, RN; Funk, ND; Hajj, GP; Hameed, T; Heistad, DD; Leinwand, LA; Lund, DD; Magida, JA; Song, LS; Weiss, RM; Zimmerman, KA, 2015) |
| "Pioglitazone is an anti-diabetic agent with recognized antifibrotic and vasculoprotective properties, which can protect smooth muscle function." | 1.40 | Pioglitazone prevents cavernosal nerve injury after radical prostatectomy. ( Aliperti, LA; Hellstrom, WJ, 2014) |
| "Pioglitazone has been demonstrated to have beneficial effects on cardiovascular outcomes." | 1.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "Myocardial fibrosis is the major factor that regulates left ventricular (LV) diastolic function." | 1.35 | Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. ( Aoki, I; Goto, T; Ito, H; Katsuta, M; Terui, G, 2009) |
| "Treatment with pioglitazone at concentrations ranging from 1 to 10 mum significantly decreased corneal fibroblast migration, as determined by scrape-wound assay, inhibited corneal fibroblast-induced collagen lattice contraction, and reduced MMP-2 and MMP-9 secretion into the supernatant of cell cultures in a dose-dependent manner." | 1.35 | Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts. ( Chen, J; Chen, M; Ma, R; Pan, H; Xu, J, 2009) |
| "Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma." | 1.32 | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (28.13) | 29.6817 |
| 2010's | 33 (51.56) | 24.3611 |
| 2020's | 13 (20.31) | 2.80 |
| Authors | Studies |
|---|---|
| Kaba, S | 1 |
| Kawai, Y | 1 |
| Tanigami, Y | 1 |
| Ohnishi, H | 1 |
| Kita, T | 1 |
| Yoshimatsu, M | 1 |
| Omori, K | 2 |
| Kishimoto, Y | 1 |
| Heath, L | 1 |
| Aveyard, P | 1 |
| Tomlinson, JW | 1 |
| Cobbold, JF | 1 |
| Koutoukidis, DA | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 1 |
| Wahid, A | 1 |
| Sanyal, AJ | 3 |
| Williams, SA | 2 |
| Lavine, JE | 2 |
| Neuschwander-Tetri, BA | 2 |
| Alexander, L | 2 |
| Ostroff, R | 2 |
| Biegel, H | 2 |
| Kowdley, KV | 2 |
| Chalasani, N | 2 |
| Dasarathy, S | 2 |
| Diehl, AM | 2 |
| Loomba, R | 2 |
| Hameed, B | 2 |
| Behling, C | 2 |
| Kleiner, DE | 2 |
| Karpen, SJ | 2 |
| Williams, J | 2 |
| Jia, Y | 2 |
| Yates, KP | 2 |
| Tonascia, J | 2 |
| An, J | 1 |
| Sohn, JH | 1 |
| Harrison, SA | 1 |
| Thang, C | 1 |
| Bolze, S | 1 |
| Dewitt, S | 1 |
| Hallakou-Bozec, S | 1 |
| Dubourg, J | 1 |
| Bedossa, P | 1 |
| Cusi, K | 2 |
| Ratziu, V | 1 |
| Grouin, JM | 1 |
| Moller, DE | 1 |
| Fouqueray, P | 1 |
| Zakariaª, EM | 1 |
| Abdel-Ghanyª, RH | 1 |
| Elgharbawyª, AS | 1 |
| Alsemehᵇ, AE | 1 |
| Metwallyª, SS | 1 |
| Kasahara, N | 1 |
| Imi, Y | 1 |
| Amano, R | 1 |
| Shinohara, M | 1 |
| Okada, K | 1 |
| Hosokawa, Y | 1 |
| Imamori, M | 1 |
| Tomimoto, C | 1 |
| Kunisawa, J | 1 |
| Kishino, S | 1 |
| Ogawa, J | 1 |
| Ogawa, W | 1 |
| Hosooka, T | 1 |
| Nhu, QM | 1 |
| Hsieh, L | 1 |
| Dohil, L | 1 |
| Dohil, R | 1 |
| Newbury, RO | 1 |
| Kurten, R | 1 |
| Moawad, FJ | 1 |
| Aceves, SS | 1 |
| Vis, DC | 1 |
| Kelly, MM | 1 |
| De Heuvel, E | 1 |
| MacEachern, PR | 1 |
| Nakano, Y | 1 |
| Arima, T | 1 |
| Tobita, Y | 1 |
| Uchiyama, M | 2 |
| Shimizu, A | 2 |
| Takahashi, H | 2 |
| Zhang, XD | 1 |
| Sun, GX | 1 |
| Guo, JJ | 1 |
| Hu, CC | 1 |
| Sun, RC | 1 |
| Yu, HC | 1 |
| Lu, Q | 1 |
| Hu, S | 1 |
| Guo, P | 1 |
| Zhu, X | 1 |
| Ren, Z | 1 |
| Wu, Q | 1 |
| Wang, X | 2 |
| Kawaguchi-Suzuki, M | 1 |
| Bril, F | 1 |
| Kalavalapalli, S | 1 |
| Frye, RF | 1 |
| Liu, C | 1 |
| Liu, R | 1 |
| Fu, H | 1 |
| Li, J | 1 |
| Cheng, L | 1 |
| Korantzopoulos, P | 1 |
| Tse, G | 1 |
| Li, G | 1 |
| Liu, T | 1 |
| Deng, W | 2 |
| Meng, Z | 1 |
| Sun, A | 1 |
| Yang, Z | 1 |
| Wei, WY | 1 |
| Zhang, N | 1 |
| Li, LL | 1 |
| Ma, ZG | 1 |
| Xu, M | 2 |
| Yuan, YP | 1 |
| Tang, QZ | 1 |
| Kanemaru, M | 1 |
| Asai, J | 1 |
| Jo, JI | 1 |
| Arita, T | 1 |
| Kawai-Ohnishi, M | 1 |
| Tsutsumi, M | 1 |
| Wada, M | 1 |
| Tabata, Y | 1 |
| Katoh, N | 1 |
| Zhang, C | 2 |
| Zhang, Y | 4 |
| Liu, Y | 2 |
| Xu, G | 2 |
| Sun, L | 1 |
| Xu, T | 1 |
| Chen, Y | 1 |
| Qu, W | 1 |
| Sun, D | 1 |
| Song, X | 1 |
| Yuan, Q | 1 |
| Yao, L | 1 |
| Németh, Á | 1 |
| Mózes, MM | 1 |
| Calvier, L | 1 |
| Hansmann, G | 1 |
| Kökény, G | 1 |
| Zhao, N | 1 |
| Yu, H | 2 |
| Sun, M | 1 |
| Gao, W | 1 |
| Masuda, Y | 1 |
| Nagasaka, S | 1 |
| Fukuda, Y | 1 |
| Aliperti, LA | 1 |
| Hellstrom, WJ | 1 |
| Yuan, M | 1 |
| Qiu, M | 1 |
| Cui, J | 1 |
| Zhang, X | 1 |
| Zhang, P | 1 |
| Chen, XQ | 1 |
| Liu, X | 1 |
| Wang, QX | 1 |
| Zhang, MJ | 1 |
| Guo, M | 1 |
| Liu, F | 1 |
| Jiang, WF | 1 |
| Zhou, L | 1 |
| Hajj, GP | 1 |
| Chu, Y | 1 |
| Lund, DD | 1 |
| Magida, JA | 1 |
| Funk, ND | 1 |
| Brooks, RM | 1 |
| Baumbach, GL | 1 |
| Zimmerman, KA | 1 |
| Davis, MK | 1 |
| El Accaoui, RN | 1 |
| Hameed, T | 1 |
| Doshi, H | 1 |
| Chen, B | 1 |
| Leinwand, LA | 1 |
| Song, LS | 1 |
| Heistad, DD | 1 |
| Weiss, RM | 1 |
| Behringer, A | 1 |
| Trappiel, M | 1 |
| Berghausen, EM | 1 |
| Ten Freyhaus, H | 1 |
| Wellnhofer, E | 1 |
| Odenthal, M | 1 |
| Blaschke, F | 1 |
| Er, F | 1 |
| Gassanov, N | 1 |
| Rosenkranz, S | 2 |
| Baldus, S | 1 |
| Kappert, K | 1 |
| Caglayan, E | 2 |
| Du, J | 1 |
| Niu, X | 1 |
| Wang, R | 1 |
| Zhao, S | 1 |
| Kong, L | 1 |
| Nan, Y | 1 |
| Wang, J | 1 |
| Zhou, QD | 1 |
| Zhang, CH | 1 |
| Li, Q | 1 |
| Huang, S | 1 |
| Zhan, J | 1 |
| Wang, K | 1 |
| Liu, YY | 1 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| Musso, G | 1 |
| Cassader, M | 1 |
| Paschetta, E | 1 |
| Gambino, R | 1 |
| Corsini, I | 1 |
| Polvani, S | 1 |
| Tarocchi, M | 1 |
| Tempesti, S | 1 |
| Marroncini, G | 1 |
| Generoso, M | 1 |
| Bresci, C | 1 |
| Gozzini, E | 1 |
| Bianconi, T | 1 |
| Galli, A | 1 |
| Dani, C | 1 |
| Oseini, AM | 1 |
| Stauber, B | 1 |
| Collins, AR | 1 |
| Lyon, CJ | 1 |
| Yin, F | 1 |
| Liu, J | 1 |
| Erdmann, E | 1 |
| Peterson, LE | 1 |
| Ross, RS | 1 |
| Tangirala, RK | 1 |
| Hsueh, WA | 1 |
| Kato, MF | 1 |
| Shibata, R | 2 |
| Obata, K | 1 |
| Miyachi, M | 1 |
| Yazawa, H | 1 |
| Tsuboi, K | 1 |
| Yamada, T | 1 |
| Nishizawa, T | 1 |
| Noda, A | 1 |
| Cheng, XW | 1 |
| Murate, T | 1 |
| Koike, Y | 1 |
| Murohara, T | 3 |
| Yokota, M | 1 |
| Nagata, K | 2 |
| Aoki, Y | 1 |
| Maeno, T | 1 |
| Aoyagi, K | 1 |
| Ueno, M | 1 |
| Aoki, F | 1 |
| Aoki, N | 1 |
| Nakagawa, J | 1 |
| Sando, Y | 1 |
| Shimizu, Y | 1 |
| Suga, T | 1 |
| Arai, M | 1 |
| Kurabayashi, M | 1 |
| Clementi, F | 1 |
| Di Luozzo, M | 1 |
| Mango, R | 1 |
| Luciani, G | 1 |
| Trivisonno, A | 1 |
| Pizzuto, F | 1 |
| Martuscelli, E | 1 |
| Mehta, JL | 1 |
| Romeo, F | 1 |
| Toblli, JE | 1 |
| Ferrini, MG | 2 |
| Cao, G | 1 |
| Vernet, D | 2 |
| Angerosa, M | 1 |
| Gonzalez-Cadavid, NF | 2 |
| Terui, G | 1 |
| Goto, T | 1 |
| Katsuta, M | 1 |
| Aoki, I | 1 |
| Ito, H | 1 |
| Makino, N | 1 |
| Maeda, T | 1 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Mimori, K | 1 |
| Li, P | 1 |
| Unno, K | 1 |
| Shimano, M | 2 |
| Furukawa, M | 1 |
| Ohashi, T | 1 |
| Cheng, X | 1 |
| Ouchi, N | 1 |
| Pan, H | 1 |
| Chen, J | 1 |
| Xu, J | 1 |
| Chen, M | 1 |
| Ma, R | 1 |
| Han, JY | 1 |
| Kim, YJ | 1 |
| Kim, L | 1 |
| Choi, SJ | 1 |
| Park, IS | 1 |
| Kim, JM | 1 |
| Chu, YC | 1 |
| Cha, DR | 1 |
| Higashi, K | 1 |
| Oda, T | 2 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 2 |
| Suzuki, S | 1 |
| Sakurai, Y | 2 |
| Miura, S | 2 |
| Kumagai, H | 1 |
| Nicolakakis, N | 1 |
| Aboulkassim, T | 1 |
| Aliaga, A | 1 |
| Tong, XK | 1 |
| Rosa-Neto, P | 1 |
| Hamel, E | 1 |
| Kume, O | 2 |
| Takahashi, N | 2 |
| Wakisaka, O | 2 |
| Nagano-Torigoe, Y | 1 |
| Teshima, Y | 2 |
| Nakagawa, M | 1 |
| Yufu, K | 1 |
| Hara, M | 2 |
| Saikawa, T | 2 |
| Yoshimatsu, H | 1 |
| Duffy, HS | 1 |
| Guo, N | 1 |
| Woeller, CF | 1 |
| Feldon, SE | 1 |
| Phipps, RP | 1 |
| Nagao, S | 1 |
| Yamaguchi, T | 1 |
| Elrashidy, RA | 2 |
| Asker, ME | 2 |
| Mohamed, HE | 2 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Fukunaga, N | 1 |
| Mizushige, K | 1 |
| Tsuji, T | 1 |
| Noma, T | 1 |
| Kawaguchi, K | 1 |
| Sakaida, I | 1 |
| Tsuchiya, M | 1 |
| Takami, T | 1 |
| Okita, K | 1 |
| Zafiriou, S | 1 |
| Stanners, SR | 1 |
| Polhill, TS | 1 |
| Poronnik, P | 1 |
| Pollock, CA | 2 |
| Panchapakesan, U | 1 |
| Sumual, S | 1 |
| Chen, X | 1 |
| Da Silva Morais, A | 1 |
| Abarca-Quinones, J | 1 |
| Horsmans, Y | 1 |
| Stärkel, P | 1 |
| Leclercq, IA | 1 |
| Kovanecz, I | 1 |
| Nolazco, G | 1 |
| Rajfer, J | 1 |
| Omasu, F | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Nakamoto, M | 1 |
| Ohya, Y | 1 |
| Shinzato, T | 1 |
| Mano, R | 1 |
| Yamazato, M | 1 |
| Sakima, A | 1 |
| Takishita, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pioglitazone Treatment in Patient's Calcific Aortic Valve Disease With Mild Aortic Valve Stenosis[NCT05875675] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent[NCT00376870] | Phase 3 | 160 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pioglitazone and Fibrosis
| Article | Year |
|---|---|
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized C | 2023 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agent | 2017 |
PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
Topics: Animals; Cardiovascular Diseases; Cell Proliferation; Disease Models, Animal; Fibrosis; Hypoglycemic | 2012 |
Novel strategy to prevent atrial fibrosis and fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Chemokine CCL2; Disease Models, Animal; Endothelial Cell | 2012 |
Pioglitazone: cardiovascular effects in prediabetic patients.
Topics: Animals; Aorta; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hypoglycemic A | 2002 |
2 trials available for pioglitazone and Fibrosis
| Article | Year |
|---|---|
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Topics: Deuterium; Diabetes Mellitus; Double-Blind Method; Fibrosis; Humans; Liver; Non-alcoholic Fatty Live | 2023 |
57 other studies available for pioglitazone and Fibrosis
| Article | Year |
|---|---|
Peroxisome Proliferator-Activated Receptor-γ Agonist Attenuates Vocal Fold Fibrosis in Rats via Regulation of Macrophage Activation.
Topics: Animals; Fibrosis; Hypoglycemic Agents; Macrophage Activation; Pioglitazone; PPAR gamma; Rats; Thiaz | 2022 |
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Topics: Fibrosis; Humans; Ligands; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Patient Reported Outc | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis.
Topics: Animals; Autophagy; Fatty Liver; Fibrosis; Inflammation; Lipids; Liver; Male; Memantine; Metabolic S | 2023 |
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells.
Topics: Animals; Diet, High-Fat; Fibrosis; Gastrointestinal Microbiome; Hepatic Stellate Cells; Humans; Lino | 2023 |
Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.
Topics: Biopsy; Budesonide; Cells, Cultured; Drug Evaluation, Preclinical; Eosinophilic Esophagitis; Esophag | 2020 |
Reduction in Alveolar Macrophage Size in Refractory Autoimmune Pulmonary Alveolar Proteinosis After Treatment With Pioglitazone.
Topics: Autoimmune Diseases; Bronchoalveolar Lavage Fluid; Fibrosis; Granulocyte-Macrophage Colony-Stimulati | 2020 |
Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
Topics: Animals; Burns, Chemical; Corneal Injuries; Corneal Neovascularization; Cytokines; Disease Models, A | 2020 |
Effects of PPARγ agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN/AKT/FAK pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Fibrosis; Focal Adhesion Kinase 1; Male; Mice; Mice, Inbre | 2021 |
PPAR-γ with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats.
Topics: Anilides; Animals; Cardiomyopathies; Cell Line; Collagen; Fibrosis; Male; Myocardium; Pioglitazone; | 2021 |
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Hypoglycemic | 2017 |
Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
Topics: Action Potentials; Alloxan; Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Expe | 2017 |
Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.
Topics: Animals; Biomarkers; Biopsy; Fibrosis; Gene Expression; Inflammation; Lipid Metabolism; Male; Mice; | 2017 |
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload.
Topics: Anilides; Animals; Cardiomegaly; Cell Differentiation; Echocardiography; Fibrosis; Hemodynamics; Hum | 2018 |
Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis.
Topics: Animals; Bleomycin; Cell Differentiation; Delayed-Action Preparations; Disease Models, Animal; Drug | 2019 |
Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator‑activated receptor γ.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Fibrosis; Gene Expression Regulation | 2019 |
Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation.
Topics: Animals; Cell Line; Fibrosis; HEK293 Cells; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbre | 2019 |
The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3.
Topics: Animals; Early Growth Response Protein 1; Fibrosis; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; | 2019 |
MiRNA-711-SP1-collagen-I pathway is involved in the anti-fibrotic effect of pioglitazone in myocardial infarction.
Topics: Animals; Blotting, Western; Cells, Cultured; Collagen Type I; Fibrosis; Gene Expression; Gene Knockd | 2013 |
An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model.
Topics: Alkalies; Animals; Burns, Chemical; Chemokines; Collagen Type III; Cornea; Corneal Neovascularizatio | 2013 |
Pioglitazone prevents cavernosal nerve injury after radical prostatectomy.
Topics: Erectile Dysfunction; Fibrosis; Humans; Male; Models, Theoretical; Muscle, Smooth; Penis; Pioglitazo | 2014 |
Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Fluorescent Antibody | 2014 |
Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway.
Topics: Adaptor Proteins, Vesicular Transport; Angiotensin II; Animals; Cell Proliferation; Fibrosis; Heart | 2015 |
Spontaneous Aortic Regurgitation and Valvular Cardiomyopathy in Mice.
Topics: Actins; Animals; Aortic Valve; Aortic Valve Insufficiency; Calcinosis; Cell Death; Disease Progressi | 2015 |
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Cardiovascular Agents; Disease Models, Animal; Fibrosis; Heart Ventricle | 2016 |
TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice.
Topics: Animals; Chemokines; Choline; Diet; Down-Regulation; Fibrosis; Inflammation; Liver; Liver Cirrhosis; | 2016 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
Topics: Animals; Chemokine CCL2; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Pioglita | 2016 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges.
Topics: Fibrosis; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidine | 2017 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Enterocoliti | 2017 |
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
Topics: Adiponectin; Angiotensin II; Animals; Cardiomegaly; Chemotaxis; Female; Fibrosis; Hypoglycemic Agent | 2008 |
Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Collagen; Echocardio | 2008 |
Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis.
Topics: Acute Lung Injury; Animals; Bleomycin; Cells, Cultured; Collagen Type I; Connective Tissue Growth Fa | 2009 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combinatio | 2009 |
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.
Topics: Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glomerulosclerosis, Focal | 2009 |
Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients.
Topics: Aged; Biomarkers; Collagen Type III; Diabetes Mellitus, Type 2; Diastole; Echocardiography; Female; | 2009 |
Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibrosis; Hypoglycemic A | 2009 |
Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone.
Topics: Adiponectin; AMP-Activated Protein Kinases; Angiotensin II; Animals; Blotting, Western; Cardiomegaly | 2010 |
Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.
Topics: Actins; Animals; Cell Line, Transformed; Cell Movement; Cell Survival; Collagen Type I; Cornea; Fibr | 2009 |
PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.
Topics: Angiotensin Receptor Antagonists; Animals; Antigens, Differentiation; Disease Models, Animal; Fibros | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord | 2011 |
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc | 2011 |
Inflammatory responses in the atria: should they stay or should they go?
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat | 2011 |
Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Topics: Cell Adhesion; Cells, Cultured; Fibroblasts; Fibrosis; Glucuronosyltransferase; Humans; Hyaluronan S | 2011 |
Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.
Topics: Amides; Animals; Antihypertensive Agents; Cardiomyopathies; Diabetic Nephropathies; Disease Models, | 2012 |
Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
Topics: Amino Acids; Animal Feed; Animals; Biomarkers; Body Weight; Choline Deficiency; Fatty Liver; Fibrosi | 2004 |
Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.
Topics: Albumins; Animals; Biological Transport, Active; Cell Division; Cells, Cultured; Chemokine CCL2; Fib | 2004 |
PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.
Topics: Cell Culture Techniques; Cell Proliferation; Fibrosis; Glucose; Humans; Hyperglycemia; Hypoglycemic | 2005 |
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
Topics: Animals; Carbon Tetrachloride; Cells, Cultured; Chemical and Drug Induced Liver Injury; Extracellula | 2007 |
Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone.
Topics: Age Factors; Animals; Blotting, Western; Collagen; Fibrosis; Immunohistochemistry; Impotence, Vascul | 2007 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |